Savara (SVRA) has been drawing attention after a recent stretch of strong share price performance, with the stock up about 13% over the past month and roughly 17% over the past 3 months.

At a share price of $5.90, Savara’s recent momentum, including a 7 day share price return of 7.27% and 30 day share price return of 13.46%, sits alongside a very strong 1 year total shareholder return of 166.97%. This suggests recent gains are part of a longer trend in how the market is reassessing the company’s risk and opportunity profile.

If you are looking beyond Savara for other ideas, this could be a useful moment to see what is standing out in the market using the 20 top founder-led companies

Given Savara’s sharp 1 year return and a market value of about $1.50b, the key question is whether the current $5.90 share price still leaves room for upside or if the market is already assuming stronger future growth.

Preferred Price-to-Book Multiple of 8.5x: Is It Justified?

With Savara trading at $5.90, the stock is valued at a P/B ratio of 8.5x, which places it at a much richer level than many peers in the biotech space.

The P/B ratio compares a company’s share price with its book value per share. For Savara, investors are currently paying 8.5 times the accounting value of its net assets. For a clinical stage biopharmaceutical company that is still loss making and generating no meaningful revenue, a higher P/B often reflects expectations around future clinical progress and potential commercialization rather than current fundamentals.

Relative to the US Biotechs industry average P/B of 2.6x and a peer group average of 5.7x, Savara’s 8.5x multiple stands out as significantly higher. This indicates that the market is putting a premium on the company’s prospects compared with both the wider industry and closer peers, even though there is insufficient data to calculate a fair P/B ratio benchmark that the valuation might trend toward over time.

Result: Price-to-book of 8.5x (OVERVALUED)

However, Savara’s current P/B premium and ongoing net loss of $129.482m mean any setbacks in its clinical program or funding plans could quickly challenge this upbeat narrative.

Next Steps

The mixed tone around Savara, with premium pricing and clear execution risks, makes this a stock where you should look closely at the underlying data. Decide quickly how you feel about the trade off between concern and optimism by reviewing the 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Savara?

If Savara has caught your attention, do not stop there. The market is full of other opportunities that could fit your style and risk tolerance.

• Spot potential bargains early by scanning 44 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their financial strength.
• Strengthen your income plan by reviewing 8 dividend fortresses that offer higher yields while still focusing on resilience and consistency.
• Reduce portfolio stress by focusing on 71 resilient stocks with low risk scores that score well on financial stability and business risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.